ES2980464T3 - Productos intermedios sintéticos útiles para preparar compuestos de aminopurina sustituidos - Google Patents

Productos intermedios sintéticos útiles para preparar compuestos de aminopurina sustituidos Download PDF

Info

Publication number
ES2980464T3
ES2980464T3 ES20214685T ES20214685T ES2980464T3 ES 2980464 T3 ES2980464 T3 ES 2980464T3 ES 20214685 T ES20214685 T ES 20214685T ES 20214685 T ES20214685 T ES 20214685T ES 2980464 T3 ES2980464 T3 ES 2980464T3
Authority
ES
Spain
Prior art keywords
amino
substituted
equiv
unsubstituted
pyran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20214685T
Other languages
English (en)
Spanish (es)
Inventor
Matthew Alexander
Sogole Bahmanyar
John Frederick Boylan
Joshua Hansen
Dehua Huang
Robert Hubbard
Brandon David Jeffy
Jim Leisten
Mehran Moghaddam
Raj Kumar Raheja
Heather Raymon
Kimberly Schwarz
Marianne Sloss
Eduardo Torres
Tam Minh Tran
Shuichan Xu
Jingjing Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signal Pharmaceuticals LLC
Original Assignee
Signal Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharmaceuticals LLC filed Critical Signal Pharmaceuticals LLC
Application granted granted Critical
Publication of ES2980464T3 publication Critical patent/ES2980464T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50Three nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES20214685T 2014-10-06 2015-10-05 Productos intermedios sintéticos útiles para preparar compuestos de aminopurina sustituidos Active ES2980464T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462060339P 2014-10-06 2014-10-06

Publications (1)

Publication Number Publication Date
ES2980464T3 true ES2980464T3 (es) 2024-10-01

Family

ID=55632334

Family Applications (2)

Application Number Title Priority Date Filing Date
ES20214685T Active ES2980464T3 (es) 2014-10-06 2015-10-05 Productos intermedios sintéticos útiles para preparar compuestos de aminopurina sustituidos
ES15848476T Active ES2871142T3 (es) 2014-10-06 2015-10-05 Compuestos de aminopurina sustituidos, composiciones de los mismos y métodos de tratamiento con los mismos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES15848476T Active ES2871142T3 (es) 2014-10-06 2015-10-05 Compuestos de aminopurina sustituidos, composiciones de los mismos y métodos de tratamiento con los mismos

Country Status (28)

Country Link
US (8) US9512124B2 (enExample)
EP (2) EP3822274B1 (enExample)
JP (4) JP6884701B2 (enExample)
KR (2) KR102504849B1 (enExample)
CN (2) CN107001372B (enExample)
AR (2) AR102171A1 (enExample)
AU (2) AU2015328414B2 (enExample)
CA (1) CA2963639C (enExample)
CL (1) CL2017000820A1 (enExample)
CO (1) CO2017003838A2 (enExample)
CY (1) CY1124173T1 (enExample)
DK (1) DK3204386T3 (enExample)
EA (1) EA201790779A1 (enExample)
EC (1) ECSP17026210A (enExample)
ES (2) ES2980464T3 (enExample)
HR (1) HRP20210656T1 (enExample)
HU (1) HUE054694T2 (enExample)
IL (2) IL251566B (enExample)
LT (1) LT3204386T (enExample)
MX (2) MX388321B (enExample)
PL (1) PL3204386T3 (enExample)
PT (1) PT3204386T (enExample)
RS (1) RS61884B1 (enExample)
SG (2) SG11201702759XA (enExample)
SI (1) SI3204386T1 (enExample)
SM (1) SMT202100302T1 (enExample)
TW (1) TW201629063A (enExample)
WO (1) WO2016057370A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102504849B1 (ko) * 2014-10-06 2023-03-02 시그날 파마소티칼 엘엘씨 치환된 아미노퓨린 화합물, 그의 조성물 및 그를 사용한 치료 방법
JP6903577B2 (ja) 2014-12-16 2021-07-14 シグナル ファーマシューティカルズ,エルエルシー 皮膚におけるc−Jun N末端キナーゼの阻害の測定方法
EP3250557B1 (en) 2015-01-29 2024-11-20 Signal Pharmaceuticals, LLC Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
JP6779899B2 (ja) 2015-03-18 2020-11-04 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Tnf阻害剤として有用なヘテロ環式化合物
JP6793657B2 (ja) 2015-03-18 2020-12-02 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 置換三環式ヘテロ環式化合物
KR102630010B1 (ko) 2015-03-18 2024-01-25 브리스톨-마이어스 스큅 컴퍼니 Tnf의 억제제로서 유용한 트리시클릭 헤테로시클릭 화합물
CN107922287B (zh) 2015-07-24 2021-04-09 细胞基因公司 合成(1r,2r,5r)-5-氨基-2-甲基环己醇盐酸盐的方法和其中可用的中间体
MX2018001173A (es) 2015-08-03 2018-04-24 Squibb Bristol Myers Co Compuestos ciclicos utiles como moduladores del factor de necrosis tumoral (tnf) alfa.
CA3018986A1 (en) 2016-04-01 2017-10-05 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
SMT202100604T1 (it) * 2016-04-01 2021-11-12 Signal Pharm Llc (1s,4s)-4-(2-(((3s,4r)-3-fluorotetraidro-2h-piran-4-il)ammino)-8-((2,4,6-triclorofenil)ammino)-9h-purin-9-il)-1-metilcicloesano-1-carbossammide e metodi per il loro utilizzo
CN109476696B (zh) * 2016-06-02 2022-06-10 细胞基因公司 动物及人抗锥虫和抗利什曼原虫剂
EP3464287B1 (en) * 2016-06-02 2022-06-08 Celgene Corporation Animal and human anti-malarial agents
EP3692041A1 (en) * 2017-10-04 2020-08-12 Celgene Corporation Processes for the preparation of cis-4 [2-{(3s.4r)-3-fluorooxan-4-yl]amino)-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]-1-methylcyclohexane-1-carboxamide
AU2018345647A1 (en) * 2017-10-04 2020-04-16 Celgene Corporation Compositions and methods of use of cis-4-(2-{((3S,4R)-3-fluorooxan-4-yl) amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide
TW202202498A (zh) * 2020-07-01 2022-01-16 大陸商四川海思科製藥有限公司 一種並環雜環衍生物及其在醫藥上的應用
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
CN114478326B (zh) * 2022-01-21 2023-10-03 安徽宁亿泰科技有限公司 一种苯嘧磺草胺关键中间体的合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US7672705B2 (en) * 2004-07-19 2010-03-02 Resonant Medical, Inc. Weighted surface-to-surface mapping
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7759342B2 (en) * 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
JP2009516707A (ja) 2005-11-18 2009-04-23 アストラゼネカ・アクチエボラーグ 固形製剤
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
EP2076516B1 (en) 2006-10-27 2013-12-11 Signal Pharmaceuticals LLC Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith
ES2400006T3 (es) 2008-04-23 2013-04-04 Farmasierra Manufacturing, S.L. Formulación farmacéutica mejorada a base de ibuprofeno y codeína
WO2011071491A1 (en) 2009-12-09 2011-06-16 Signal Pharmaceuticals, Llc Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US8680076B2 (en) 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
US8603527B2 (en) 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
WO2014172616A2 (en) 2013-04-18 2014-10-23 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
KR102504849B1 (ko) 2014-10-06 2023-03-02 시그날 파마소티칼 엘엘씨 치환된 아미노퓨린 화합물, 그의 조성물 및 그를 사용한 치료 방법
SMT202100604T1 (it) 2016-04-01 2021-11-12 Signal Pharm Llc (1s,4s)-4-(2-(((3s,4r)-3-fluorotetraidro-2h-piran-4-il)ammino)-8-((2,4,6-triclorofenil)ammino)-9h-purin-9-il)-1-metilcicloesano-1-carbossammide e metodi per il loro utilizzo

Also Published As

Publication number Publication date
IL277069A (en) 2020-10-29
US20170042902A1 (en) 2017-02-16
CA2963639C (en) 2023-07-04
EP3822274B1 (en) 2024-03-06
KR20230035424A (ko) 2023-03-13
EP3204386B1 (en) 2021-03-03
US9737541B2 (en) 2017-08-22
IL251566B (en) 2020-09-30
AU2020201486A1 (en) 2020-03-19
CN113248506A (zh) 2021-08-13
HRP20210656T1 (hr) 2021-07-23
US20200237768A1 (en) 2020-07-30
AR128748A2 (es) 2024-06-12
CA2963639A1 (en) 2016-04-14
US20190091230A1 (en) 2019-03-28
KR20170063740A (ko) 2017-06-08
CY1124173T1 (el) 2022-05-27
BR112017006998A2 (pt) 2018-01-16
US10398700B2 (en) 2019-09-03
US10646493B2 (en) 2020-05-12
IL251566A0 (en) 2017-05-29
SG11201702759XA (en) 2017-05-30
CL2017000820A1 (es) 2017-12-15
NZ767954A (en) 2024-02-23
TW201629063A (zh) 2016-08-16
EP3822274A1 (en) 2021-05-19
SG10202009598VA (en) 2020-10-29
ECSP17026210A (es) 2017-05-31
PT3204386T (pt) 2021-05-31
JP2017530199A (ja) 2017-10-12
RS61884B1 (sr) 2021-06-30
CO2017003838A2 (es) 2017-07-11
US20170296546A1 (en) 2017-10-19
AU2020201486B2 (en) 2021-07-08
AU2015328414A1 (en) 2017-04-27
MX2021014531A (es) 2022-01-06
NZ730753A (en) 2024-02-23
US20190336507A1 (en) 2019-11-07
MX388321B (es) 2025-03-19
US11590139B2 (en) 2023-02-28
US9512124B2 (en) 2016-12-06
MX2017004600A (es) 2017-06-30
AU2015328414B2 (en) 2020-03-19
US20160096841A1 (en) 2016-04-07
US10940152B2 (en) 2021-03-09
JP2020033352A (ja) 2020-03-05
CN107001372B (zh) 2021-04-27
LT3204386T (lt) 2021-07-12
WO2016057370A1 (en) 2016-04-14
US20210128565A1 (en) 2021-05-06
JP6884701B2 (ja) 2021-06-09
US20230158035A1 (en) 2023-05-25
EA201790779A1 (ru) 2017-09-29
ES2871142T3 (es) 2021-10-28
AR102171A1 (es) 2017-02-08
US10149849B2 (en) 2018-12-11
HUE054694T2 (hu) 2021-09-28
JP7196270B2 (ja) 2022-12-26
KR102504849B1 (ko) 2023-03-02
DK3204386T3 (da) 2021-05-25
CN107001372A (zh) 2017-08-01
JP2022033858A (ja) 2022-03-02
EP3204386A4 (en) 2018-04-18
SMT202100302T1 (it) 2021-07-12
JP6987823B2 (ja) 2022-01-05
IL277069B (en) 2022-05-01
JP2023027269A (ja) 2023-03-01
SI3204386T1 (sl) 2021-08-31
EP3204386A1 (en) 2017-08-16
PL3204386T3 (pl) 2021-09-20

Similar Documents

Publication Publication Date Title
ES2980464T3 (es) Productos intermedios sintéticos útiles para preparar compuestos de aminopurina sustituidos
ES3009308T3 (en) Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
US10420772B2 (en) Animal and human anti-trypanosomonal and anti-leishmania agents
BR112017006998B1 (pt) Composto de aminopurina substituído, composição farmacêutica compreendendo o mesmo, uso e método para preparar o referido composto e métodos in vitro e ex vivo de inibição de quinase
HK1241852B (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith